Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 23

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 23
---
th) Trading Day thereafter and (c) the applicable Adjustment Price and Adjustment Share
Amount for such exercised Purchase Warrants shall be calculated as stated in the previous paragraph.

<div align='center'>10</div>

The Purchase Warrants also
contain anti-dilution protection (subject to the floor price of $0.084) against Dilutive Issuances (as defined in the Purchase Warrants),
whereby the exercise price and the number of shares of Common Stock underlying the Purchase Warrants is subject to reset in the same manner
as described above.

The exercise price (subject
to the floor price of $0.084) and number of shares of Common Stock underlying the Purchase Warrants will also reset if there occurs any
share split, reverse share split, share dividend, share combination recapitalization or other similar transaction involving the Company’s
Common Stock (each, a “Share Combination Event”) and the lowest Weighted Average Price of the Common Stock during the period
commencing on the trading day immediately following the applicable Share Combination Event and ending on the fifth (5th) trading day immediately
following the applicable Share Combination Event Date is less than the Exercise Price then in effect in the same manner described above.

In addition, a holder of
Series B Warrants may, at any time and in its sole discretion, exercise its Series B Warrants in whole or in part by means of a “zero
exercise price” option in which the holder is entitled to receive a number of shares of Common Stock that shall equal the product
of (x) the aggregate number of shares of Common Stock that would be issuable upon exercise of the Series B Warrant in accordance with
its terms if such exercise were by means of a cash exercise rather than through the zero exercise price option and (y) 3. As a result
of this feature, we do not expect to receive any cash proceeds from the exercise of the Series B Warrants because it is highly unlikely
that a Series B Warrant holder will elect to pay an exercise price in cash to receive one share of common stock when they could elect
the zero exercise price option in these circumstances to receive more shares of common stock than they would receive if they did pay
an exercise price. As an example, given the above provisions, holders of the Series B Warrants will be issued a maximum of 1,085,714,550
shares of Common Stock upon the exercise of the Series B Warrants. Each Series B Warrant includes one underlying share of